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Abstract
Background: Imported cases of infections due to Dengue (DENV) and Chikungunya (CHIKV) viruses and, more recently,
Zika virus (ZIKV) are commonly reported among travelers returning from endemic regions. In areas where potentially
competent vectors are present, the risk of autochthonous transmission of these vector-borne pathogens is relatively high.
Laboratory surveillance is crucial to rapidly detect imported cases in order to reduce the risk of transmission. This study
describes the laboratory activity performed by the National Reference Laboratory for Arboviruses (NRLA) at the Italian
National Institute of Health in the period from July 2014 to October 2015.
Methods: Samples from 180 patients visited/hospitalized with a suspected DENV/CHIKV/ZIKV infection were sent to the
NRLA from several Italian Hospitals and from Regional Reference Laboratories for Arboviruses, in agreement with the
National Plan on human surveillance of vector-borne diseases. Both serological (ELISA IgM test and Plaque Reduction
Neutralization Test—PRNT) and molecular assays (Real Time PCR tests, RT-PCR plus nested PCR and sequencing of
positive samples) were performed.
Results: DENV infection was the most frequently diagnosed (80 confirmed/probable cases), and all four genotypes
were detected. However, an increase in imported CHIKV cases (41 confirmed/probable cases) was observed, along with
the detection of the first ZIKV cases (4 confirmed cases), as a consequence of the recent spread of both CHIKV and ZIKV
in the Americas.
Conclusions: Main diagnostic issues highlighted in our study are sensitivity limitations of molecular tests, and the
importance of PRNT to confirm serological results for differential diagnosis of Arboviruses. The continuous evaluation of
diagnostic strategy, and the implementation of laboratories networks involved in surveillance activities is essential to
ensure correct diagnosis, and to improve the preparedness for a rapid and proper identification of viral threats.
Background
Vector-borne viral diseases cause a substantial public
health burden in tropical and sub-tropical regions. Their
geographic distribution is expanding, due to many and
complex factors, such as urbanization, climate change,
land-use changes, human mobility, and vector range ex-
pansion [1].
The Dengue virus (DENV) is a flavivirus (family Flaviviri-
dae) transmitted to humans through Aedes (Ae.) spp mos-
quito bite. Dengue fever is typically characterized by fever,
myalgia, arthralgia, rash, and sometimes severe and life-
threatening clinical symptoms. Dengue global incidence has
increased 30-fold in the last 50 years [2], and areas with
predominant circulation of a single DENV serotype have
changed toward co-circulation of different virus serotypes
[3]. During the past decade, additional mosquito-borne vi-
ruses, including Chikungunya virus (CHIKV) and Zika
virus (ZIKV), have successfully spread to geographical areas
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where only dengue epidemics used to be reported [3–8].
CHIKV is an alphavirus (family Togaviridae) that causes an
acute febrile illness characterized by severe arthralgia,
whereas ZIKV, another mosquito-borne flavivirus closely
related to DENV, mostly causes mild fever, joint pain, con-
junctivitis, and rash [3]. As for DENV, CHIKV and ZIKV
are transmitted between humans by Ae. species mosquitoes
[9, 10]. Since 2004, CHIKV has caused epidemics in Africa,
Asia, and Indian Ocean islands. In 2007 an outbreak of chi-
kungunya originated from an imported case coming from
India occurred in Italy, causing more than 200 cases of dis-
ease [11]. In December 2013, CHIKV was notified in the
Caribbean and has since spread to several countries in the
Americas [7, 12]. The first outbreak of ZIKV outside Africa
and Asia was reported in 2007 in the Yap State, Federated
States of Micronesia [13]. Subsequently, in 2013, this virus
reappeared in French Polynesia and then spread through-
out the Pacific. In the early 2015, the first local transmission
of ZIKV was reported in Brazil [14]. Since then, the infec-
tion has rapidly spread throughout South America, Central
America, and the Caribbean [8, 15, 16], and recently in
Florida, USA [17]. ZIKV, previously thought to be associ-
ated with a mild clinical disease, was found to be associated
with a 20-fold increase in the Guillain-Barrè syndrome inci-
dence following the French Polynesia outbreak [18]. More-
over, the report of a possible association between ZIKV
infection and an epidemic of microcephaly among neonates
in Brazil has attracted global attention, and has led the
World Health Organization (WHO) to declare the ZIKV
epidemic as a global public health emergency on February,
1st 2016 [19]. In the meanwhile, evidence supporting the
association between ZIKV infection and neonatal micro-
cephaly and other birth defects has increased [20–25].
Imported cases of illness due to DENV and CHIKV,
and more recently ZIKV, are reported every year among
travelers returning from endemic regions [26–28]. In
areas where competent vectors are present, the risk of
autochthonous transmission of these vector-borne path-
ogens is particularly high [11, 29]. Thus, epidemiological
and laboratory surveillance is crucial to rapidly identify
imported cases in order to introduce measures to reduce
risks for public health. The aim of the present study is
to present data on imported infections in Italy, diag-
nosed at the National Reference Laboratory for Arbovi-
ruses (NRLA) in the period from July 2014 to October
2015, mainly focusing on diagnostic issues, countries of
origin of the infections, and viral strains involved in the
imported cases.
Methods
Patients and samples
Samples of patients visited/hospitalized with a suspected
DENV/CHIKV/ZIKV infection, collected from July 2014
through October 2015, were analyzed. A case-report
form containing information about age, sex, countries
visited, travel dates, and date of onset of symptoms was
completed for each patient. Samples were collected and
sent to the NRLA at the Istituto Superiore di Sanità in
Rome from several Italian Hospitals, in agreement with
the National Plan on human surveillance of imported
and autochthonous vector-borne diseases (CHIKV,
DENV, ZIKV, and West Nile virus—WNV) [30, 31].
Samples were sent also from Regional Reference Labora-
tories for Arboviruses involved in the surveillance Na-
tional Plan for diagnostic confirmation and/or with the
aim of a cross-evaluation of the diagnostic methods used
in different laboratories. ELISA IgM and real time PCR
tests were performed for a first line diagnosis. Plaque
Reduction Neutralization Tests (PRNTs) were performed
to confirm positive results obtained by ELISA tests, and
to discriminate between closely related viruses.
Serological assays
ELISA IgM
IgM antibodies against DENV, CHIKV, and ZIKV were
detected in patients serum samples using commercial
IgM-capture ELISA systems (Focus Diagnostics Dengue
Virus IgM Capture, DxSelect™, California, USA, NovaLisa®
Chikungunya IgM μ-capture ELISA, NovaTec Immun-
diagnostica GmbH, Germany, Euroimmun Anti-Zika
Virus IgM ELISA, Luebeck, Germany). Absorbance was
measured at 450 nm using an ELISA reader, according to
manufacturer’s instructions. Sample optical density read-
ings were compared with reference cut-off OD readings to
determine results. Index values >1.00 for DENV, > 11.00
for CHIKV, and > 1,1 for ZIKV were considered presump-
tive for the presence of IgM antibodies.
Plaque Reduction Neutralization test (PRNT)
The assay was performed in six-well tissue culture plates
with subconfluent VERO cell monolayers (approximately
70% confluence). The following viruses were used: sero-
type 2 DENV (NGB strain), a CHIKV strain isolated
from a patient during the 2007 Italian outbreak [11], and
ZIKV H/PF/2013 strain of the Asian genotype (kindly
provided by Dr. Isabelle Leparc-Goffart of the French
National Reference Center on Arboviruses in Marseille)
[32]. Infectivity titration of each viral strain was per-
formed by plaque assay using VERO cells. Patients sera
were diluted 1:10 in serum-free maintenance medium,
heat-inactivated, and titrated in duplicate in twofold di-
lution steps. Equal volumes (100 μl) of DENV/CHIKV/
ZIKV dilution containing approximately 80 Plaque
Forming Units (PFU), and serum dilutions, were mixed,
and incubated overnight at 4 °C. Subsequently, VERO
cells plates were infected with 200 μl/well of virus-serum
mixtures in duplicate. After 1 h incubation at 37 °C and
5% CO2, the inocula were aspirated and the wells were
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overlayed with a mixture of one part 2% Gum Tragacanth
and one part of supplemented medium (2× MEM, 2.5%
inactivated FCS and 2% 1 M HEPES). The plates were in-
cubated at 37 °C and 5% CO2 for 2 (CHIKV) - 7 (DENV)
- 4 (ZIKV) days, and then were stained with 1.5% crystal
violet. A titration of CHIK/DEN/ZIK viruses with three di-
lutions in duplicate (the working dilution, 1:2 and 1:8 dilu-
tions) was performed in each assay and used as a control
for the assay. Neutralizing antibody titers were calculated
as the reciprocal of the serum dilution that gave a 50 or
80% reduction of the number of plaques (PRNT50/
PRNT80), as compared to the virus control. PRNT80 ≥ 10
were considered positive, while PRNT50 ≥ 10 were con-
sidered as border line (b.l.).
Molecular diagnosis
RNA extraction and Real Time PCRs
Molecular tests were performed on acute sera of DENV/
CHIKV/ZIKV-suspected patients.Viral RNA was ex-
tracted from 140 μl of serum sample by using QIAmp
viral RNA Mini kit (Qiagen Inc., Valencia, CA, USA), ac-
cording to the manufacturer’s instructions, and then
stored at -80 °C until further processing. The RNA was
amplified by real time PCR for CHIKV, DENV, and/or
ZIKV detection. The primers and probes used in this
study are listed in Table 1 [11, 33, 34]. All real time PCR
assays were performed by using the RealTime ready
RNA Virus Master mix (Roche Diagnostics, Basel, CH),
according to the manufacturer’s protocol, and CFX96
Touch™ Real-Time PCR Detection System (Bio-Rad).
Amplification and sequencing from viral RNA
For DENV and CHIKV nucleic acid detection and geno-
typing, Reverse Transcription (RT)-PCR followed by
nested PCR amplification was performed. An amplicon of
434 bp in the E gene region and an amplicon of 536 bp in
the E1 structural glycoprotein coding gene region were
obtained for DENV an CHIKV, respectively. The primers
used for RT-PCR plus nested PCR and sequencing are
listed in Table 2 [35, 36]. SuperScript One-step RT-PCR
with Platinum Taq kit (Invitrogen, Gaithersburg, MD) and
Platinum PCR SuperMix kit (Invitrogen) were used for
RT-PCR and nested PCR, respectively. PCR products were
purified by QIAquick PCR Purification Kit (Qiagen) and
were sequenced on both strands by using nested forward
and reverse primers.
Table 1 Primers and probes for the molecular diagnosis
Primers and Probes Sequence (5’- 3’) Reference
DenS GGATAGACCAGAGATCCTGCTGT [33]
DenAs + DenAs1 CATTCCATTTTCTGGCGTTC + CAATCCATCTTGCGGCGCTC
DenP FAM-CAGCATCATTCCAGGCACAG-TAMRA
ChikS TGATCCCGACTCAACCATCCT [11]
ChikAs GGCAAACGCAGTGGTACTTCCT
ChikP FAM-TCCGACATCATCCTCCTTGCTGGC-Black Hole Quencher 1
Zvf1086 CCGCTGCCCAACACAAG [34]
Zvr1162c CCACTAACGTTCTTTTGCAGACAT
ZvP_1107 6FAM-AGCCTACCTTGACAAGCAGTCAGACACTCAA-TAMRA
Table 2 Primers for DENV and CHIKV amplification and
sequencing
Primers Sequence (5’- 3’) Reference
RT-PCR: [35]
DEUL TGGCTGGTGCACAGACAATGGTT
DEUR GCTGTGTCACCCAGAATGGCCAT
Nested PCR:
DENUL GATCTCAAGAAGGAGCCATGCA
DENUR ATGGAACTTCCCTTCTTGAACCA
RT-PCR: [36]
CHIK 10264 F GGCGCCTACTGCTTCTG
CHIK 11300R CGACACGCATAGCACCSC
Nested PCR:
CHIK 10564 F CCCTTTGGCGCAGGAAGAC
CHIK 11081R GACTTGTACGCGGAATTCGG
Table 3 Case definition on the bases of the diagnostic test results
Confirmed PCR positive and/or IgM positive plus PRNT positivea, and/or
seroconversion or four fold increase in neutralizing antibody
titers in two consecutive samples.
Probable IgM positive plus PRNT border lineb in acute samplesc.
Possible IgM negative and PRNT positive/border line, or IgM positive
but PRNT negative in acute samples.
Not
confirmed
IgM positive and PRNT negative in late/convalescent
samples, or PRNT positive without an increase in the titer in
two consecutive samples.
aPRNT80 ≥ 10: positive
bPRNT50 ≥ 10: border line (b.l.)
cThese cases were classified as possible if PRNT b.l. results were obtained
toward different viruses
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Phylogenetic analysis
The sequences obtained were aligned with other
DENV/CHIKV sequences available in the GenBank
database (accession numbers are reported in the
phylogenetic trees), by using the ClustalW program
(www.clustal.org) [37]. Alignments were manually
edited with the Bioedit program [38]. Nucleotide
Tamura-Nei model and the Neighbour-Joining method
was used to construct the phylogenetic trees [39]. The
Neighbour-Joining method was implemented by using
MEGA version 6.06 (www.megasoftware.net) [40]. The
robustness of branching patterns was confirmed with a
bootstrap analysis using 1000 replicates.
Results
Dengue, Chikungunya and Zika diagnostic tests results,
and areas of origin of the imported infections
Samples collected from 180 patients visited/hospitalized
with a suspected DENV/CHIKV/ZIKV infection were ana-
lyzed. Of the patients, 50,6% were males, median age was
38 years (range 1–80 years). For 116 patients for whom
the information about the date of symptoms onset and/or
hospitalization was available, the median lag time before
sample collection was 8 days (range 2–102 days, mean ±
standard deviation: 15,47 ± 18,24 days). Two serum sam-
ples (acute phase and convalescence phase) were available
from 27 patients. Samples were sent to the NRLA from
several Italian Regions (Friuli Venezia Giulia, Lombardia,
Piemonte, Liguria, Toscana, Umbria, Lazio, Abruzzo,
Campania, Sardegna, Calabria e Sicilia). Most of the sam-
ples were collected during the summertime, from June to
September, when the surveillance is increased because of
vector activity.
On the base of diagnostic tests results, and clinical and
epidemiological data, each case was defined as confirmed,
probable, possible or not confirmed, according to the cri-
teria shown in Table 3.
In the study period, a total of 157 patients were tested
for DENV, 97 for CHIKV and 16 for ZIKV (Table 4).
Overall, 68 DENV cases (plus 12 probable cases), 35
CHIKV cases (plus 6 probable cases), and 4 ZIKV cases
[27, 41] were confirmed, plus two cases of ZIKV past
infection. For 76 patients, diagnostic tests both for DENV
and for CHIKV were performed, and 2 cases of possible co-
infections were detected. Clinical features of DENV, CHIKV
and ZIKV confirmed/probable cases are shown in Table 5.
Table 4 DENV, CHIKV and ZIKV diagnosis in the period from July 2014 to October 2015
Total Confirmed Probable Possible Not confirmed
DENV diagnosis 157 68 12 33 44
CHIKV diagnosis 97 35 6 14 42
ZIKV diagnosis 16 4a 0 3b 9
Dual diagnosis
DENV/CHIKV
76: two cases of possible
co-infections.
DENV: 18/76 (of which two CHIKV confirmed
and one CHIKV possible cases)
CHIK: 20/76 (of which two DENV confirmed
and 6 DENV possible cases)
aThe diagnosis of one of these cases was performed in Germany after we excluded DENV and CHIKV infections (ref). One was a case of autochthonous (most likely
sexual) transmission (ref)
bOf these, two were probable cases of past ZIKV infections (PRNT positives and IgM negatives). One showed instead a PRNT b.l. result for ZIKV, which was
probably due to cross reactivity of DENV specific antibodies
Table 5 Clinical features of DENV, CHIKV and ZIKV confirmed/probable cases
Symptoms DENV confirmed and probable cases
presenting with the symptoma
CHIKV confirmed and probable cases
presenting with the symptoma
ZIKV confirmed and probable cases
presenting with the symptoma
Fever (≥38 °C) 93,2% 92,6% 75,0%
Arthralgia 71,2% 96,3% 75,0%
Rash 33,9% 66,7% 100,0%
Asthenia 76,3% 70,4% 25,0%
Headache 62,7% 37,0% 0,0%
Myalgia 52,6% 63,0% 25,0%
Retro-orbital pain 32,2% 11,1% 0,0%
Meningoencephalitis 1,7% 3,7% 0,0%
Others 10,2%b 3,7% c 0,0%
aSymptoms were known for 59, 27 and 4 DENV, CHIKV and ZIKVV cases, respectively
bdiarrhea, vomit, leuco-thrombocytopenia
csymptoms persisting for longer than 30 days
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The area of origin of the suspected imported cases was
known for 62 DENV, 30 CHIKV, and 4 ZIKV confirmed/
probable cases DENV cases were imported from many dif-
ferent countries in all continents except Europe. Among
DENV confirmed/probable cases, 59.7% were from Asia,
17.7% from Central and South America, 11.3% from the
Caribbean, 6.5% from Africa, and 4.8% from Oceania. As
expected, because of the recent CHIKV epidemics in the
Americas, among the CHIKV confirmed/probable cases,
53.3% were from the Caribbean, 36.7% were from Central
and South America, and only 10.0% were from Asia
or Africa. Two ZIKV confirmed infections had been
acquired in Brazil, one in March [27] and one in
May, 2015, while one had been acquired in Thailand
in 2014, and one was an autochthonous case likely
due to sexual transmission [41].
Serological diagnosis of DENV, CHIKV and ZIKV infections
ELISA IgM tests
Results of ELISA IgM tests are summarized in Table 6.
DENV ELISA IgM test was performed for 127 of 157
patients tested for DENV, with 55 positive results; for
14.5% of the ELISA IgM positive patients, a final diagno-
sis of confirmed or probable DENV infection was not
done after considering all laboratory findings and avail-
able epidemiological data. These cases are likely to rep-
resent false positive IgM ELISA results. Conversely,
11.1% of the ELISA IgM negative patients were diag-
nosed as confirmed DENV cases on the basis of other
tests (PCR positivity) and/or of IgM results obtained by
the hospital/laboratory where the sample had been col-
lected (not shown); they were considered as false nega-
tives. Of note, of the DENV suspected cases coming to
our laboratory with a positive IgM result obtained in the
hospital/laboratory where the sample had been collected
(n = 53) (not shown), 24.5% (13/53) could not be con-
firmed by PRNT nor by molecular tests.
CHIKV ELISA IgM test was performed for 86 of 97
patients tested for CHIKV, with 3 b.l. results, and 31
positive results; all positive ELISA IgM results and two
of the b.l. were confirmed by a positive or b.l. PRNT re-
sult. Among 52 CHIKV ELISA IgM negative samples, 13
were positive and 4 b.l. in PRNT: of these, at least 5
(9.6%) were considered to be associated with a recently
acquired infection, based on clinical and epidemiological
data, and thus estimated as probable false-negative
ELISA results. Of the CHIKV suspected cases coming to
our laboratory with a positive IgM result obtained in the
hospital/laboratory where the sample had been collected
(n = 27) (not shown), 11.1% (3/27) were classified as not
confirmed after evaluation of all laboratory findings.
ZIKV IgM test was performed for 5 patients, all with a
PRNT positive result for ZIKV: 3 were positive, and
were thus considered as recent, confirmed, ZIKV infec-
tions, while the two IgM negatives were considered as
past infections.
Overall, 94 DENV and 40 CHIKV ELISA IgM results
could be compared with the IgM results obtained with
different methods in the hospital/laboratory of origin of
the samples (not shown): concordant results were ob-
tained in 81.9 and 87.5% of cases for DENV and CHIKV,
respectively.
PRNTs
PRNTs results are summarized in Table 7: neutraliz-
ing antibodies were detected in 79/157 (50.3%) of
patients tested for DENV, in 47/97 (48.4%) of patients
tested for CHIKV, and in 5/15 (33,3%) of patients
tested for ZIKV. In 26/79 (32,9%) of DENV PRNT
positive patients, 10/47 (21,2%) of CHIKV PRNT
positive patients, and 2/5 (40%) of ZIKV PRNT posi-
tive patients, both molecular tests and ELISA IgM
gave negative results: these subjects had probably ac-
quired a DENV and/or CHIKV infection in the past,
which was not associated with the recent/ongoing ill-
ness. A b.l. PRNT result was obtained for 31 of 157
DENV tested patients. Of these, 10 (32.3%) were clas-
sified as confirmed cases, since the viral genome
could be detected in the same sample, and/or a fully
positive PRNT result was obtained in a second, con-
valescent sample. Moreover, 12 (38.7%) were classified
Table 6 DENV/CHIKV/ZIKV ELISA IgM tests results
ELISA IgM:
positives/tested
Estimated proportion of false
positive and false negative
test results
DENV (Focus
Diagnostics Dengue
Virus IgM Capture,
DxSelect™)
55/127 8/55 (14.5%) false positives
8/72 (11.1%) false negatives
CHIKV (NovaLisa®
Chikungunya IgM
μ-capture ELISA,
NovaTec
Immundiagnostica)
31 + 3 b.l./86 1 b.l./86 (1,2%) false positives
5/52 (9,6%) false negatives
ZIKV (Euroimmun
IgM ELISA)
3/5
Table 7 DENV/CHIKV/ZIKV PRNTs results
PRNT positives/tested PRNT border line/tested
DENV 79/157 (50.3%) 31/157
(19,7%)
10/31 (32.3%): confirmed cases
12/31 (38.7%): probable cases
9/31 (29%): possible cases
CHIKV 47/97 (48.4%) 11/97
(11,3%)
1/11 (9%): confirmed case
4/11 (36,4%): probable cases
6/11 (54,6%): possible cases
ZIKV 5/15 (33,3%) 1/15
(6,7%)
possible case (probable cross
reactivity of DENV specific
neutralizing antibodies)
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as probable cases, since a positive ELISA IgM results was
obtained in the same sample. Finally, 9 (29%) PRNT b.l.
results were obtained from cases defined as possible,
which were not associated with any other positive result
(n = 5), and/or associated with a confirmed infection by a
closely related Flavivirus (ZIKV, n = 3), and/or in cases
showing b.l. PRNT results also for different viruses (such
as CHIKV and WNV, n = 3), suggesting a broad and non
DENV-specific cross-reactivity. With respect to CHIKV
diagnosis, a b.l. PRNT result was obtained for 11 (11.3%)
of 97 CHIKV tested patients: one from a confirmed case,
4 from probable cases, and 6 which were classified as pos-
sible cases, since they were not associated with positive re-
sults in other CHIKV tests, and, in 3 cases, presented b.l.
PRNT results also for different viruses (such as DENV
and WNV). Finally, one b.l. PRNT result was obtained for
ZIKV, in a sample of a DENV confirmed case.
Molecular diagnosis of DENV and CHIKV infections, and
phylogenetic analysis of viral sequences
For DENV diagnosis, 25 of 132 (18.9%) samples tested by
real time PCR gave a positive result. All PCR positive sam-
ples (for which the time from the onset of symptoms was
known), had been collected within 8 days from the onset
of symptoms (mean ± standard deviation: 4.71 ± 1.76 days).
For CHIKV diagnosis, only 2/76 (2.6%) samples tested by
real time PCR gave a positive result, which had been col-
lected 3 days after the onset of symptoms. All samples an-
alyzed for ZIKV by real time PCR gave negative results.
Among all samples collected within 8 days from the
onset of symptoms, CHIKV viral genome was detected
in 7.7% (2/26) of the samples (22.2% of confirmed/
probable cases), and DENV viral genome in 36.8% (21/
57) of tested samples (53.8% of confirmed/probable
cases). These data may suggest a longer duration of
Table 8 DENV and CHIKV sequences characterized in this study
Isolate ID Travel location Genotype Year isolated GenBank accession no.
DENV-1
S2014-358 Thailand I-Asian 2014 LN870423
S2014-376 Bali, Indonesia I-Asian 2014 LN870425
S2015-510 ? I-Asian 2015 LN999960
S2015-460 French_Polynesia I-Asian 2015 LN999954
S2015-475 Philippines IV-South Pacific 2015 LN999955
S2015-423 Oceania IV-South Pacific 2015 LN879497
S2014-383 Manila, Philippines IV-South Pacific 2014 LN870426
S2015-431 Maldives V-African/American 2015 LN879498
S2015-458 Maldives V-African/American 2015 LN999951
S2015-481 Mexico V-African/American 2015 LN999958
S2015-425 Haiti V-African/American 2015 LN879499
DENV-2
S2014-368 ? Cosmopolitan 2014 LN870428
S2015-477 Maldives Cosmopolitan 2015 LN999956
S2015-512 ? Cosmopolitan 2015 LN999961
S2015-409 Thailand Cosmopolitan 2015 LN999950
S2015-465 Thailand Cosmopolitan 2015 LN999952
S2015-482 India Cosmopolitan 2015 LN999959
S2015-478 Thailand and Cambodia Cosmopolitan 2015 LN999957
S2014-382 Santo Domingo, Dominican Republic America/Asian 2014 LN870427
DENV-3
S2015-517 ? III 2015 LN999962
S2014-339 Cuba III 2014 LN870424
DENV-4
S2015-466 Thailand I 2015 LN99995
CHIKV
S2015-416 ? Asian 2015 LN879501
S2015-422 Colombia Asian 2015 LN879500
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Table 9 DENV and CHIKV reference sequences
Virus strain Location Genotype Year isolated GenBank accession no.
DENV-1
NC14-17042014-4554 New Caledonia I-Asian 2014 KM212960
China/GD-D13001 Thailand I-Asian 2013 KJ545455
DENV-1/8/Thailand/01/2013 Thailand I-Asian 2013 KF887994
Khabar 2759 Khabarovsk, Far East, Russia I-Asian 2012 KJ417841
SL_2012_GS0319 Sri-Lanka I-Asian 2012 KJ26662
MKS-WS81 Indonesia I-Asian 2010 KC762639
D1/Vietnam/1012aTw Viet Nam I-Asian 2010 JF967953
Thailand 2010 Thailand I-Asian 2010 JN415528
D1/IDN/Bali_033/2010 Indonesia I-Asian 2010 KM216676
- Cambodia I-Asian 1998 AF309641
GZ/80 China I-Asian 1980 AF350498
PUO 359 Thailand I-Asian 1980 AF425630
16007 Thailand II-Thailand 1964 AF180817
TH-SMAN Thailand II-Thailand 1954 D10513
P72-1244 Malaysia III-sylvatic 1972 EF457905
D1/Hu/Philippines/NIID13/2016 Philippines IV-South Pacific 2016 LC128301
FI/DB170/2014 Fiji IV-South Pacific 2014 KM279390
Phil2012 Philippines IV-South Pacific 2012 KR919819
Philippines 2010 Philippines IV-South Pacific 2010 JN415517
WS01/190801-769 Samoa IV-South Pacific 2001 JQ655095
A88 Indonesia IV-South Pacific 1988 AB074761
AUS HCS1 Australia IV-South Pacific 1983 AF425611
PRS 228682 Philippines IV-South Pacific 1974 AF425627
Guangzhou/2014/4 China V-African/American 2015 KT751343
Wenzhou-Human-1 China V-African/American 2014 KR024708
9/D1/Del/2013 India V-African/American 2013 KU166895
AO/DB132/2013 Angola V-African/American 2013 KM277610
DENV-1/NI/BID-V7696/2012 Nicaragua V-African/American 2012 KF973475
ARC-73-12 Puerto Rico V-African/American 2012 KF444913
D1/Mexico/Ixtaczoquitlan/17/2007 Mexico V-African/American 2007 HM171564
ThD1_0673_80 Thailand V-African/American 1980 AY732474
715393 India V-African/American 1971 JF297579
IBH 28328 Nigeria V-African/American 1968 AF425625
DENV-2
SG(EHI)D2/18944Y13 Singapore Cosmopolitan 2013 KR779784
D2/IDN/Lombok_087/2012 Bali, Indonesia Cosmopolitan 2012 KM216718
D2/IDN/Bali_103/2012 Bali, Indonesia Cosmopolitan 2012 KM216731
D2/THA/086/2012 Thailand Cosmopolitan 2012 KM216717
D2/TLS/Timor_078/2012 East Timor Cosmopolitan 2012 KM216712
D2/IDN/Bali_108/2012 Indonesia Cosmopolitan 2012 KM216736
12/GZ/12851 China Cosmopolitan 2012 KF060919
D2/IDN/Bali_075/2011 Bali, Indonesia Cosmopolitan 2011 KM216709
D2/IN/RGCB921/2011 India Cosmopolitan 2011 KF364514
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Table 9 DENV and CHIKV reference sequences (Continued)
10/GZ/11864 China Cosmopolitan 2010 JN009092
Philippines 2010b Philippines Cosmopolitan 2010 JN568265
D2/IDN/Jakarta_060/2010 Indonesia Cosmopolitan 2010 KM216708
SG(EHI)D2/63481Y10 Singapore Cosmopolitan 2010 JN030340
DENV-2/VN/BID-V735/2006 Viet Nam Cosmopolitan 2006 EU482672
D2/SG/05K3330DK1/2005 Singapore Cosmopolitan 2005 EU081178
GWL177 INDI-01 India Cosmopolitan 2001 DQ448236
2784-DF-11/18/2002 Taiwan Cosmopolitan 2002 DQ645556
MD922 Viet Nam Asian II 2003 GU434156
40247 Brazil Asian II 1990 L10041
ThD2_0284_90 Thailand Asian II 1990 DQ181801
PR/DB189/2013 Puerto Rico American/Asian 2013 KM279409
DR59/01 Dominican Republic American/Asian 2001 AB122022
Cuba115/97 Cuba American/Asian 1997 AY702050
IQT-1950 Perù American 1995 DQ917242
D2/TO/UH04/1974 Tonga American 1974 HM582117
Laos 2010 Laos Asian I 2010 JN568244
D2/Myanmar/1007aTw Myanmar Asian I 2010 JF968026
D2/LAO/043/2010 Laos Asian I 2010 KM216697
D2/Laos/1007aTw Laos Asian I 2010 JF968021
DENV-2/KH/BID-V2062/2007 Cambodia Asian I 2007 GQ868624
Myan0207a/Tw Myanmar Asian I 2002 DQ518651
DENV-2/TH/BID-V2311/2001 Thailand Asian I 2001 FJ744725
GD08/98 China Asian I 1998 FJ196851
ThD2_0168_79 Bangkok, Thailand Asian I 1979 DQ181805
DAK Ar 2022 Burkina Faso sylvatic 1980 DQ917247
DAK Ar 2039 Burkina Faso sylvatic 1980 DQ917246
DENV-3
D3/IDN/Bali_007/2010 Indonesia I 2010 KM216737
D3/Malaysia/1012bTw Malaysia I 2010 JF968112
H87 Philippines I 1987 M93130
80-2 China I 1980 AF317645
D3-73NIID Japan I 1973 AB111085
LN2632 Malaysia II 1999 AF147459
D89-273 Thailand II 1989 AY145715
PaH881/88 Thailand II 1988 AF349753
ThD3_0046_83 Thailand II 1983 AY676358
ThD3_0040_80 Thailand II 1980 AY676359
ThD3_0033_74 Thailand II 1974 AY676360
D3BR/ST14/04 Brazil III 2004 DQ118882
- Singapore III 2004 AY662691
D3PY/AS12/02 Paraguay III 2002 DQ118884
BR74886/02 Brazil III 2002 AY679147
Cuba_167_2001 Cuba III 2001 KT726341
Cuba580/01 Cuba III 2001 AY702030
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Table 9 DENV and CHIKV reference sequences (Continued)
D3/H/IMTSSA-SRI/2000/1266 Sri Lanka III 2000 AY099336
00-28-1HuNIID Cambodia III 2000 AB111081
6883/YUCATAN-MX/97 Yucatan III 1997 DQ341204
1339 Puerto Rico IV 1997 AY146761
Human, Tahiti 1965 Tahiti IV 1965 L11439
DENV-4
D4/RL196/Myanmar/2013 Myanmar I 2013 KJ470765
D4/Thailand/0702aTw Thailand I 2007 EU448454
D4/Cambodia/0509aTw Cambodia I 2005 EU448455
ThD4_0485_01 Thailand I 2001 AY618992
ThD4_1142_98 Thailand I 1998 AY618980
ThD4_0348_91 Bangkok, Thailand I 1991 AY618990
SPH317947 Brazil II 2011 JN092553
DENV-4/VE/BID-V1156/2007 Venezuela II 2007 GQ868645
DENV-4/CO/BID-V3412/2005 Colombia II 2005 CQ868585
D4MY02-26658 Malaysia II 2002 FN429922
8976/95 Singapore II 1995 AY762085
D4/PR/M35/1985 Puerto Rico II 1985 GU318316
ThD4_0476_97 Bangkok, Thailand III 1997 AY618988
ThD4_0017_97 Bangkok, Thailand III 1997 AY618989
P75-514 Malaysia IV 1975 AF231723
P73-1120 Malaysia IV 1973 AF231724
CHIKV
10Mdy105 Myanmar East Central South African 2010 KF590567
GD139 China East Central South African 2010 HQ846358
TN06310 India East Central South African 2010 HM159388
CU-Chik_OBF Thailand East Central South African 2009 GU908223
0901aTw Malaysia East Central South African 2009 FJ807895
0812bTw Malaysia East Central South African 2008 FJ807893
CU-Chik10 Thailand East Central South African 2008 GU301780
FD080178 China East Central South African 2008 GU199352
0810aTw Bangladesh East Central South African 2008 FJ807898
SGEHICHT077808 Singapore East Central South African 2008 FJ445484
ITA07-RA1 Italy East Central South African 2007 EU244823
DRDE-07 India East Central South African 2007 EU372006
LR2006_OPY1 Reunion East Central South African 2006 DQ443544
0611aTw Singapore East Central South African 2006 FJ807896
SL11131 Sri Lanka East Central South African 2006 AB455493
06-027 Reunion East Central South African 2005 AM258993
UgAg4155 Uganda East Central South African 1982 HM045812
Vereeniging South Africa East Central South African 1956 HM045792
S27-African prototype Tanzania East Central South African 1953 AF369024
Ross low-psg Tanzania East Central South African 1953 HM045811
TR206/H804187 Brazil Asian 2014 KP164572
0811aTw Indonesia Asian 2008 FJ807891
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viremia in DENV infection compared to CHIKV
infection.
Sequences were obtained for 22 of the DENV PCR
positive samples, and for the 2 CHIKV PCR positive
samples. Both nucleic acid and translated amino acid se-
quences were aligned with GenBank sequences of iso-
lates with known dates and locations, and phylogenetic
analysis was performed. Viral strains and genotypes, lo-
cations of origin, year of the infections, and Gene Bank
accession numbers are summarized in Tables 8 (se-
quences characterized in this study) and Table 9 (refer-
ence sequences). As shown in Fig. 1a,b,c and d, DENV
strains of all the four serotypes were identified (11
DENV-1, 8 DENV-2, two DENV-3 and one DENV-4
strains). Within the DENV-1 serotype, 4 strains grouped
together with the Asian lineage (genotype I), 3 with the
South Pacific lineage (Genotype IV) and 4 with African/
American lineage (Genotype V), with bootstrap values ≥
97 (Fig. 1a). Most of DENV-1 sequences (from patients
S2015-423, S2015-475, S2014-376, S2015-510, S2015-
470, S2015-425, S2015-481, S2015-458, S2015-431)
showed a high similarity with GenBank strains known to
circulate in the areas of origin of the imported infections
(88–98% homology at nucleic acid level and 100% at
amino acid level). In contrast, two of our DENV-1 se-
quences showed a higher degree of divergence when
compared to DENV-1 sequences available in Gene Bank.
A strain from Philippines, identified in the patient
S2014-383, showed the highest similarity (88% homology
at nucleic acid level and 93% at amino acid level), with
two strains from Philippines collected in previous years
(acc. n° JN415517 collected in 2010; acc. n° KR919819
collected in 2012). Moreover, the phylogenetic analysis
of the strain S2014-358 from Thailand, showed the
higher similarity (86% homology at nucleic acid level
and 92% at amino acid level) with a Gene Bank Thai
strain collected in 2010 (acc. n° JN415528). The strain
S2014-358 showed the same 92% similarity at amino
acid level also with other Thai strains collected in 2013
(acc. n° KJ545455 and KF887994). In Fig. 1b is reported
the DENV-2 tree: 7 out of 8 strains (S2014-368, S2015-
409, S2015-465, S2014-482, S2015-477, S2014-478 and
S2015-512) clustered in the Cosmopolitan genotype: 4 of
them (S2015-409, S2015-465, S2015-478, S2015-482),
from Thailand and India, showed a high similarity with
Indian isolates sequences (2001-DQ448236 and 2011-
KF364514) both at nucleic acid and amino acid level
(90–98% and 100% respectively). The S2014-382 se-
quence, from Santo Domingo, clustered in the American/
Asian genotype, showing a strong homology (85 and 100%
in nucleic and amino acid composition, respectively) with
the strain collected in Puerto Rico in 2013 (acc. n°
LN870427). The two DENV-3 strains identified in this
study (S2014-339 from Cuba, and S2015-517 from un-
known geographic area) clustered in genotype III, showing
93–100% of identity with the GenBank strains collected in
Central American and Caribbean areas (acc. n° DQ341204
and level (Fig. 1c). The DENV-4 sequence (S2015-466,
from Thailand) showed a strong homology with an isolate
collected in 2013 from Myanmar area (acc. n° KJ470765)
(similarity of 90 and 100% at nucleic and amino acid level,
respectively), and distance values of 73–80% at nucleic
acid level and 83–93% at amino acid level, with other
sequences of different years from Thailand (acc. n°
AY618990 collected in 1991, AY618980 collected in 1998,
AY618992 collected in 2001, and EU448454 collected in
2007) (Fig. 1d). CHIKV sequences obtained from patients
S2015-416 (for which the geographic area of origin of the
infection was not known) and S2015-422, from Colombia,
were aligned with 30 GenBank sequences with known
dates and locations. From the analysis of the phylogenetic
tree, the two sequences were shown to belong to the Asian
genotype (Fig. 2). The S2015-416 sequence showed a 100%
identity both at nucleic and amino acid level with an iso-
late collected in 2008 in Indonesia (acc. n° KC879577).
The S2015-422 sequence showed the strongest homology
with a Brazilian isolate (acc. n° KP164572) (98 and 96%
similarity at nucleic and amino acid level, respectively).
Discussion
In this study, we present the results of laboratory diag-
nosis of imported Arbovirus infections in Italy, in the
period from July 2014 to October 2015. As it is well
known, dengue is endemic throughout the tropics and
subtropics, and its global prevalence has grown dramat-
ically in recent years. Indeed, we found that DENV
Table 9 DENV and CHIKV reference sequences (Continued)
2008900245-BDG E1 Indonesia Asian 2008 KC879577
MY021IMR/06/BP Malaysia Asian 2006 EU703762
PhH15483 Philippines Asian 1985 HM045790
Gibbs 63-263 India Asian 1963 HM045813
TH35 Thailand Asian 1958 HM045810
HD 180760 Senegal West African 2005 HM045817
37997 Senegal West African 1983 AY726732
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infection was the most frequently detected imported
arboviral infection among our patients. Moreover, all
four known DENV genotypes were detected. An increase
in imported CHIKV cases was also observed, as already
documented in Spain, mainland France, and Northern
Italy, along with the first identification of ZIKV imported
cases; both findings are attributable to the recent dra-
matic spread of both CHIKV and ZIKV in previously
Fig. 1 Neighbour-Joining phlylogenetic analysis of sequences obtained from DENV positive samples using Tamura-Nei model with 1000 bootstrap
reiterations. For each sequence, GenBank accession number/viral genotype/country of origin of the infection/year of the infection are reported.
Sequences characterized in this study are indicated by a black square. The bars indicate the percentage of diversity. Bootstrap values over 80%
obtained from 1000 replicate trees are shown for key nodes. a: DENV-1 genotypes; b: DENV-2 genotypes; c: DENV-3 genotypes; d: DENV-4 genotypes
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unaffected areas [27, 42–44]. The continuous expansion of
the areas with Arbovirus circulation, together with the dis-
persion of Aedes mosquitoes spp., which are known or
might be competent vectors [45], may increase the risk of
outbreaks also in temperate climate areas. In Italy, the
widespread presence of Ae. albopictus throughout the coun-
try, and the recent introduction and spread of new species
[46, 47], make this risk particularly high. However, no au-
tochthonous transmission chains have been recorded in our
country in the period between July 2014 and October 2015.
The widespread circulation of CHIKV and ZIKV in
areas until recently known to be endemic only for DENV
represents a matter of concern for the potential risk of
introduction in temperate regions, and raises significant
diagnostic issues. In particular, problems related to the
broad cross-reactivity of closely related viral agents, and
the lack of well validated and standardized, commercially
available tests (as it is for ZIKV), or the non-optimal per-
formance of available tests, particularly when different
viral agents co-circulate in the same areas, need to be
Fig. 2 Neighbour-Joining phlylogenetic analysis of sequences obtained from CHIKV positive samples using Tamura-Nei model with 1000 bootstrap
reiterations. For each sequence, GenBank accession number/viral genotype/country of origin of the infection/year of the infection are reported.
Sequences characterized in this study are indicated by a black square. The bars indicate the percentage of diversity. Bootstrap values over 80%
obtained from 1000 replicate trees are shown for key nodes
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addressed. To this regard, ZIKV imported cases are in-
creasingly being reported, as a consequence of the con-
tinuous spread of the infection in south and central
America [16, 48], leading to an increase in the requests for
diagnosis. Criticisms in ZIKV diagnosis have been out-
lined recently [16], particularly for pregnant women [49],
following the alert for the possible association between
this infection and neonatal microcephaly [50].
From this scenario, the need for a careful evaluation of
the diagnostic tools available for these infections clearly
emerges. At this aim, in this work we have defined “our”
criteria for case definition (Table 3) on the basis of the
results of the diagnostic tests routinely used in our la-
boratory. However, it must be underlined that the final
case definition for each patient is up to the clinician, and
at this aim criteria are well defined in the National Plan
for Arbovirus surveillance [30, 31] issued annually by
the Italian Ministry of Health.
Molecular approaches for the diagnosis of viral infec-
tions are the most rapid as well as sensitive and specific.
Moreover, sequencing and phylogenetic analysis of de-
tected viruses can contribute to the knowledge of circu-
lating viral strains and of the degree of their genetic
variability. However, as suggested by our data, the use of
molecular techniques is limited by the short duration of
viremia during the course of the infection. With respect
to serological diagnosis, we assessed some limitations in
the sensitivity and/or specificity of the ELISA IgM kits
routinely used in our laboratory, and also some degree
of discrepancy with IgM results obtained by different la-
boratories. We have estimated approximately 14.5% of
false positive and 11.0% false negative results for DENV,
and approximately 9.6% of false negatives for CHIKV.
Although the main purpose of our study was not a
detailed analysis of the performances of different IgM
detection systems, our data strengthen the need to con-
firm the diagnosis of cases defined as probable on the
basis of IgM tests results. With respect to the PRNT, we
have defined as “borderline” results those in which
50%,(i.e., less than 80%) of plaque reduction was ob-
served. We found that b.l. PRNT results can be obtained
in different situations. In most cases, they can be ob-
served in samples collected soon after the onset of
symptoms, and can be considered as an early, specific,
response to the infection. In some cases, however, b. l.
PRNT results can be due to infection by a closely related
virus: we have observed a b.l. PRNT result for ZIKV in a
DENV confirmed, DENV PRNT positive case; and, con-
versely, a DENV b.l. PRNT result in a ZIKV confirmed,
ZIKV PRNT positive case. Indeed, even if PRNT is con-
sidered the most specific test, there can be some degree
of cross-reactivity, thus b.l. PRNT results should always
be considered cautiously. Finally, few cases showed b.l.
PRNT results for several viruses (such as DENV, CHIKV
and WNV), which probably represents a non-specific re-
sponse of unknown origin, maybe due to an underlying,
still undefined pathology.
Conclusion
DENV infection was the most frequently diagnosed cause
of illness among travelers, and all four genotypes were de-
tected. An increase in imported CHIKV cases and the first
imported ZIKV cases were detected. Major diagnostic is-
sues highlighted in our study are sensitivity limitations of
molecular tests, and the importance of PRNT to confirm
serological results for the differential diagnosis of Arbovi-
ruses. Moreover, the implementation of a network of la-
boratories involved in surveillance activities throughout
the country may greatly improve the preparedness for a
rapid a proper recognition of a possible autochthonous
outbreak. Finally, the continuous evaluation of laboratory
findings in the context of surveillance activities can be of
great importance for the development of novel diagnos-
tics, and for field evaluation of the impact of viral diseases,
also in view of vaccine development and use.
Abbreviations
Ae.: Aedes; b.l.: Border line; CHIKV: Chikungunya virus; DENV: Dengue virus;
ISS: Istituto Superiore di Sanità; NRLA: National Reference Laboratory for
Arboviruses; PCR: Polymerase chain reaction; PRNT: Plaque Reduction
Neutralization Test; WHO: World Health Organization; WNV: West Nile virus;
ZIKV: Zika virus
Acknowledgements
The Arbovirus Working Group: Alessia Caratelli1, Veronica Bizzotti1, Daniela
Casale1, Debora Lepore1, Valentina Cecchetti1, Maria Grazia Caporali3, Licia
Bordi4, Fabrizio Carletti4, Francesca Colavita4, Eleonora Lalle4, Serena Quartu4,
Lisa Malincarne10, Ilaria Caracciolo11, Claudia Tiberio12, Erasmo Falco12. The
authors would like to thank all health professionals and clinicians from local
and regional health authorities for collaborating. Maria Grazia Ciufolini for
critically revising the manuscript and fruitful discussion.
Funding
None.
Availability of data and materials
Viral Sequences obtained in this study are available in the GenBank database
(accession numbers are reported in the phylogenetic trees).
Authors’ contributions
GV, CF, MER and GR designed and managed this study. CR, AB, GR are involved in
the epidemiological surveillance at ISS. GR is the head of the Department of
Infectious, Parasitic and Immune-Mediated Diseases of the Istituto Superiore di
Sanità (ISS). EB, CF, CF, MER, GV performed laboratory investigations at ISS. MER
and CA performed phylogenetic analysis. GV, CF, MER and FF prepared and
analysed the data. GV, CF, MER and GR contributed in writing the manuscript. CC,
MRC, LZ, AB, NZ, MRG, LCN, GV, FB, PDA, GS are all involved in Arbovirus
Surveillance activities, as clinicians or as responsible of Regional Reference
Laboratories. All persons of the Arbovirus Working Group, both of the ISS and of
Regional Reference Laboratories, contributed in laboratory investigation, and in
preparing and analyzing the data. All authors read and approved the final
manuscript and contributed proofreading this manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Fortuna et al. BMC Infectious Diseases  (2017) 17:216 Page 13 of 15
Ethics approval and consent to participate
In this study, no experiments involving recruitment of humans, nor animals, have
been performed. A retrospective, aggregate analysis has been performed on
human data (such as travels, symptoms, etc) from surveillance activity and from
diagnostic activity performed on human clinical samples, in agreement with a
National Plan issued and revised annually by Italian Ministry of Health, for which
an ethics approval is not required (Decreto legislativo 24 giugno 2003, n. 211.
Attuazione della direttiva 2001/20/CE relativa all’applicazione della buona pratica
clinica nell’esecuzione delle sperimentazioni cliniche di medicinali per uso clinico).
No data attributable to individual patients are presented in this manuscript.
Clinical samples from suspected disease cases have all been collected by hospitals
from several Italian Regions, according to Italian law (Decreto legislativo 30 giugno
2003, n. 196. Codice in materia di protezione dei dati personali).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
2National Center for Epidemiology and Health Promotion, Istituto Superiore
di Sanità, Rome, Italy. 3Laboratory of Virology, National Institute for Infectious
Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy. 4Infectious and Tropical
Diseases Unit, Careggi University Hospital, Florence, Italy. 5Department of
Experimental and Clinical Medicine, University of Florence, Florence, Italy.
6Clinical Microbiology, Virology and Bioemergency, Luigi Sacco Hospital,
Milan, Italy. 7Virology Section and Retrovirus Centre of the Department of
Translational Research NSMT, University of Pisa, Pisa University Hospital
(Azienda Ospedaliero-Universitaria Pisana), Pisa, Italy. 8Department of
Laboratory Diagnosis, Palermo University Hospital (Azienda Ospedaliera
Universitaria Policlinico Palermo), Palermo, Italy. 9Clinic of Infection Diseases,
Department of Medicine, University of Perugia, Perugia, Italy. 10Department
of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
11Institute for Maternal and Child Health—IRCCS Burlo Garofolo, Trieste, Italy.
12UOC Microbiology and Virology, Hospital for Infectious Diseases “D.
Cotugno”, AO dei Colli (Monaldi, Cotugno, CTO), Naples, Italy.
Received: 3 December 2016 Accepted: 10 March 2017
References
1. Suk JE, Semenza JC. From global to local: vector-borne disease in an
interconnected world. Eur J Public Health. 2014;24(4):531–2.
2. World Health Organization. Global strategy for dengue prevention and
control 2012-2020. 2012.
3. Cao-Lormeau VM, Musso D. Emerging arboviruses in the Pacific. Lancet.
2014;384(9954):1571–2.
4. Weaver SC. Arrival of chikungunya virus in the new world: prospects for
spread and impact on public health. PLoS Negl Trop Dis. 2014;8(6):e2921.
5. Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, Matheus S, Leparc-
Goffart I, Flusin O, Prat C, Cesaire R, Najioullah F, Ardillon V, Balleydier E,
Carvalho L, Lemaitre A, Noel H, Servas V, Six C, Zurbaran M, Leon L, Guinard A,
van den Kerkhof J, Henry M, Fanoy E, Braks M, Reimerink J, Swaan C, Georges
R, Brooks L, Freedman J, Sudre B, Zeller H. Chikungunya outbreak in the
Caribbean region, December 2013 to March 2014, and the significance for
Europe. Euro Surveill. 2014;19(13):20759.
6. Nunes MR, Faria NR, de Vasconcelos JM, Golding N, Kraemer MU, de Oliveira
LF, Azevedo Rdo S, da Silva DE, da Silva EV, da Silva SP, Carvalho VL, Coelho
GE, Cruz AC, Rodrigues SG, Vianez Jr JL, Nunes BT, Cardoso JF, Tesh RB, Hay
SI, Pybus OG, Vasconcelos PF. Emergence and potential for spread of
Chikungunya virus in Brazil. BMC Med. 2015;13:102. 015-0348-x.
7. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X.
Chikungunya in the Americas. Lancet. 2014;383(9916):514. 6736(14)60185-9.
8. Musso D, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of
dengue and chikungunya? Lancet. 2015;386(9990):243–4.
9. Vega-Rua A, Lourenco-de-Oliveira R, Mousson L, Vazeille M, Fuchs S, Yebakima
A, Gustave J, Girod R, Dusfour I, Leparc-Goffart I, Vanlandingham DL, Huang YJ,
Lounibos LP, Mohamed Ali S, Nougairede A, de Lamballerie X, Failloux AB.
Chikungunya virus transmission potential by local aedes mosquitoes in the
americas and europe. PLoS Negl Trop Dis. 2015;9(5):e0003780.
10. Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009;15(9):1347–50.
11. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P,
Fortuna C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG,
Majori GC, Cassone A, CHIKV study group. Infection with chikungunya virus
in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840–6.
12. Feldstein LR, Ellis EM, Rowhani-Rahbar A, Halloran EM, Ellis BR. The First
Reported Outbreak of Chikungunya in the U.S. Virgin Islands, 2014-2015. Am
J Trop Med Hyg. 2016;95(4):885–89.
13. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick
M, Marfel M, Holzbauer S, Dubray C, Guillaumot L, Griggs A, Bel M, Lambert
AJ, Laven J, Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB. Zika
virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med.
2009;360(24):2536–43.
14. Zanluca C, de Melo VC, Mosimann AL, Dos Santos GI, Dos Santos CN, Luz K.
First report of autochthonous transmission of Zika virus in Brazil. Mem Inst
Oswaldo Cruz. 2015;110(4):569–72.
15. European Centre for Disease Prevention and Control (ECDC). Rapid Risk
Assessment. Zika virus infection outbreak, Brazil and the Pacific region. 2015.
16. Fauci AS, Morens DM. Zika virus in the Americas - yet another arbovirus
threat. N Engl J Med. 2016;374(7):601–4.
17. McCarthy M. Four in Florida are infected with Zika from local mosquitoes.
BMJ. 2016;354:i4235.
18. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, Baudouin L,
Mallet H, Musso D, Ghawche F. Zika virus infection complicated by Guillain-
Barre syndrome–case report, French Polynesia, December 2013. Euro
Surveill. 2014;19(9):20720.
19. World Health Organization. WHO statement on the first meeting of the
International Health Regulations (2005) (IHR 2005) Emergency Committee
on Zika virus and observed increase in neurological disorders and neonatal
malformations. 2016.
20. Brasil P, Pereira Jr JP, Raja Gabaglia C, Damasceno L, Wakimoto M, Ribeiro
Nogueira RM, Carvalho de Sequeira P, Machado Siqueira A, Abreu de
Carvalho LM, Cotrim da Cunha D, Calvet GA, Neves ES, Moreira ME,
Rodrigues Baiao AE, Nassar de Carvalho PR, Janzen C, Valderramos SG,
Cherry JD, Bispo de Filippis AM, Nielsen-Saines K. Zika Virus Infection in
Pregnant Women in Rio de Janeiro - Preliminary Report. N Engl J Med.
2016;375(24):2321–34.
21. Martines RB, Bhatnagar J, Keating MK, Silva-Flannery L, Muehlenbachs A,
Gary J, Goldsmith C, Hale G, Ritter J, Rollin D, Shieh WJ, Luz KG, Ramos AM,
Davi HP, Kleber de Oliveria W, Lanciotti R, Lambert A, Zaki S. Notes from the
field: evidence of zika virus infection in brain and placental tissues from two
congenitally infected newborns and two fetal losses - Brazil, 2015. MMWR
Morb Mortal Wkly Rep. 2016;65(6):159–60.
22. Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, Kolenc M,
Resman Rus K, Vesnaver Vipotnik T, Fabjan Vodusek V, Vizjak A, Pizem J,
Petrovec M, Avsic Zupanc T. Zika Virus Associated with Microcephaly. N
Engl J Med. 2016;374(10):951–8.
23. Sarno M, Sacramento GA, Khouri R, do Rosario MS, Costa F, Archanjo G,
Santos LA, Nery Jr N, Vasilakis N, Ko AI, de Almeida AR. Zika Virus Infection
and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal
Demise. PLoS Negl Trop Dis. 2016;10(2):e0004517.
24. Schuler-Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A,
Doriqui MJ, Neri JI, Neto JM, Wanderley HY, Cernach M, El-Husny AS, Pone MV,
Serao CL, Sanseverino MT, Brazilian Medical Genetics Society-Zika Embryopathy
Task Force. Possible Association Between Zika Virus Infection and Microcephaly
- Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(3):59–62.
25. Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, Araujo ES, de
Sequeira PC, de Mendonca MC, de Oliveira L, Tschoeke DA, Schrago CG,
Thompson FL, Brasil P, Dos Santos FB, Nogueira RM, Tanuri A, de Filippis AM.
Detection and sequencing of Zika virus from amniotic fluid of fetuses with
microcephaly in Brazil: a case study. Lancet Infect Dis. 2016;16(6):653–60.
26. Lagi F, Zammarchi L, Strohmeyer M, Bartalesi F, Mantella A, Meli M, Blanc P,
Tacconi D, Farese A, Zanelli G, Pippi F, Aquilini D, Tonziello A, Nencioni C,
Benvenuti M, Moneta S, Furnari F, Ciufolini MG, Nicoletti L, Bartoloni A.
Imported dengue fever in Tuscany, Italy, in the period 2006 to 2012. J Travel
Med. 2014;21(5):340–3.
27. Zammarchi L, Tappe D, Fortuna C, Remoli ME, Gunther S, Venturi G,
Bartoloni A, Schmidt-Chanasit J. Zika virus infection in a traveller returning
to Europe from Brazil, March 2015. Euro Surveill. 2015;20(23):21153.
28. Napoli C, Salcuni P, Pompa MG, Declich S, Rizzo C. Estimated imported
infections of Chikungunya and Dengue in Italy, 2008 to 2011. J Travel Med.
2012;19(5):294–7.
Fortuna et al. BMC Infectious Diseases  (2017) 17:216 Page 14 of 15
29. Avsic-Zupanc T. Mosquito-borne diseases–a new threat to Europe? Clin
Microbiol Infect. 2013;19(8):683–4.
30. Ministero della Salute, Direzione Generale della Prevenzione Sanitaria, Ufficio V,
Malattie Infettive e Profilassi Internazionale ex-DGPREV: Sorveglianza dei casi
umani di Chikungunya, Dengue, West Nile Disease ed altre arbovirosi e
valutazione del rischio di trasmissione in Italia - 2015. Circolare 16 giugno 2015.
31. Ministero della Salute, Direzione Generale della Prevenzione Sanitaria, Ufficio
V, Malattie Infettive e Profilassi Internazionale ex-DGPREV: Sorveglianza dei
casi umani delle malattie trasmesse da vettori con particolare riferimento a
Chikungunya, Dengue, Zika virus e West Nile Disease, 2014. Circolare 30
giugno 2014, n° 17674.
32. Baronti C, Piorkowski G, Charrel RN, Boubis L, Leparc-Goffart I, de Lamballerie X:
Complete coding sequence of zika virus from a French polynesia outbreak in
2013. Genome Announc 2014, 2(3):10.1128/genomeA.00500-14.
33. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, Gunther S.
Rapid detection and quantification of RNA of Ebola and Marburg viruses,
Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus,
dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J
Clin Microbiol. 2002;40(7):2323–30.
34. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield
SM, Duffy MR. Genetic and serologic properties of Zika virus associated with an
epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14(8):1232–9.
35. Yenchitsomanus PT, Sricharoen P, Jaruthasana I, Pattanakitsakul SN,
Nitayaphan S, Mongkolsapaya J, Malasit P. Rapid detection and
identification of dengue viruses by polymerase chain reaction (PCR).
Southeast Asian J Trop Med Public Health. 1996;27(2):228–36.
36. Edwards CJ, Welch SR, Chamberlain J, Hewson R, Tolley H, Cane PA, Lloyd
G. Molecular diagnosis and analysis of Chikungunya virus. J Clin Virol. 2007;
39(4):271–5.
37. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity
of progressive multiple sequence alignment through sequence weighting,
position-specific gap penalties and weight matrix choice. Nucleic Acids Res.
1994;22(22):4673–80.
38. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis
program for Windows 95/98/NT. Nucleic Acids Symp Ser. 1999;41:95–8.
39. Saitou N, Nei M. The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol Biol Evol. 1987;4(4):406–25.
40. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5:
molecular evolutionary genetics analysis using maximum likelihood,
evolutionary distance, and maximum parsimony methods. Mol Biol Evol.
2011;28(10):2731–9.
41. Venturi G, Zammarchi L, Fortuna C, Remoli ME, Benedetti E, Fiorentini C,
Trotta M, Rizzo C, Mantella A, Rezza G, Bartoloni A: An autochthonous case
of Zika due to possible sexual transmission, Florence, Italy, 2014. Euro
Surveill 2016, 21(8):10.2807/1560-7917.ES.2016.21.8.30148.
42. Paty MC, Six C, Charlet F, Heuze G, Cochet A, Wiegandt A, Chappert JL,
Dejour-Salamanca D, Guinard A, Soler P, Servas V, Vivier-Darrigol M, Ledrans
M, Debruyne M, Schaal O, Jeannin C, Helynck B, Leparc-Goffart I, Coignard B.
Large number of imported chikungunya cases in mainland France, 2014: a
challenge for surveillance and response. Euro Surveill. 2014;19(28):20856.
43. Rossini G, Gaibani P, Vocale C, Finarelli AC, Landini MP. Increased number of
cases of Chikungunya virus (CHIKV) infection imported from the Caribbean
and Central America to northern Italy, 2014. Epidemiol Infect. 2016;144(9):
1912–6.
44. Requena-Mendez A, Garcia C, Aldasoro E, Vicente JA, Martinez MJ, Perez-
Molina JA, Calvo-Cano A, Franco L, Parron I, Molina A, Ruiz M, Alvarez J,
Sanchez-Seco MP, Gascon J. Cases of chikungunya virus infection in
travellers returning to Spain from Haiti or Dominican Republic, April-June
2014. Euro Surveill. 2014;19(28):20853.
45. Di Luca M, Severini F, Toma L, Boccolini D, Romi R, Remoli ME, Sabbatucci
M, Rizzo C, Venturi G, Rezza G, Fortuna C. Experimental studies of
susceptibility of Italian Aedes albopictus to Zika virus. Euro Surveill. 2016;
21(18):10.2807/1560-7917.ES.2016.21.18.30223.
46. Capelli G, Drago A, Martini S, Montarsi F, Soppelsa M, Delai N, Ravagnan S,
Mazzon L, Schaffner F, Mathis A, Di Luca M, Romi R, Russo F. First report in
Italy of the exotic mosquito species Aedes (Finlaya) koreicus, a potential
vector of arboviruses and filariae. Parasit Vectors. 2011;4:188. 3305-4-188.
47. Montarsi F, Drago A, Martini S, Calzolari M, De Filippo F, Bianchi A, Mazzucato M,
Ciocchetta S, Arnoldi D, Baldacchino F, Rizzoli A, Capelli G. Current distribution of
the invasive mosquito species, Aedes koreicus [Hulecoeteomyia koreica] in
northern Italy. Parasit Vectors. 2015;8:614. 015-1208-4.
48. Attar N. ZIKA virus circulates in new regions. Nat Rev Microbiol. 2016;14(2):62.
49. Petersen EE, Staples JE, Meaney-Delman D, Fischer M, Ellington SR,
Callaghan WM, Jamieson DJ. Interim guidelines for pregnant women during
a zika virus outbreak - United States, 2016. MMWR Morb Mortal Wkly Rep.
2016;65(2):30–3.
50. European Centre for Disease Prevention and Control (ECDC). Rapid risk
assessment: Microcephaly in Brazil potentially linked to the Zika virus
epidemic. 2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fortuna et al. BMC Infectious Diseases  (2017) 17:216 Page 15 of 15
